/

BCDA

BioCardia, Inc.Closed

0.9903−0.03 −2.91%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.02

Prev close

1.02

Day range

0.98001.03

52-week range

0.75001.80

Volume

67.98K0.26×

Mkt cap

14.99M

P/E ttm

—

Fwd P/E

-1.71

EPS ttm

-0.6400

Div yield

0.00%

Earnings

—

From 52w high

−44.98%

Price Chart

Yahoo Finance · delayed

BCDAOct 13, 2026O 1.0200H 1.0300L 0.9800C 0.9900−0.0300 (−2.94%)Vol 68.00K

SMA 501.0542
SMA 2001.1010

1Y change −26.12% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BCDA BioCardia, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.60%
1 month: −8.33%
3 months: +23.75%
6 months: −16.10%
Year to date: −20.80%
1 year: −34.44%

Valuation & ownership

Market cap: 14.99M
Enterprise value: 11.17M
P/E (ttm): —
Forward P/E: -1.71
PEG ratio: —
Price / book: 5.50
Price / sales (ttm): —
EV / EBITDA: -1.51
EPS (ttm): -0.6400
EPS (forward): -0.5800
Beta (5y monthly): 0.62
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 15.14M
Float: 12.26M
Short % of float: 4.66%
Short ratio (days): 1.83
Held by insiders: 17.92%
Held by institutions: 14.79%
Avg volume (3m): 263.60K
50-day average: 1.05
200-day average: 1.10
52-week change: −34.44%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 41.4
vs 50-day SMA: −6.09%
vs 200-day SMA: −10.09%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.63%
Realised vol (20d, ann.): 63.0%
From 52-week high: −45.00%
From 52-week low: +32.00%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

15.50

+1,465.18% implied

Low 6.00Median 15.50High 25.00

Recommendation trend

Now2 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About BioCardia, Inc.

Yahoo Finance profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 17
Headquarters: Sunnyvale, CA, United States
Website: biocardia.com
Officers: Dr. Peter A. Altman Ph.D. CEO, President & Director
Mr. David McClung Chief Financial Officer
Mr. Edward M. Gillis Senior Vice President of Devices

SEAS

Seasonality · BCDA

2007–2026 · monthly returns

Strongest month Sep +21.14%Weakest month Mar −9.76%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-1.6	4.9	-6.2	-5.8	-18.4	33.3	-33.9	39.0	-11.4	-2.0			−20.8%
2025	13.3	-18.6	26.4	23.6	-31.2	-9.7	9.7	-7.5	-34.8	8.5	3.6	-13.8	−42.7%
2024	-31.8	22.2	-25.5	-4.9	-21.0	-35.7	1.3	1.3	2.3	-25.3	-2.1	-4.4	−78.0%
2023	21.5	-13.4	-11.4	5.6	-14.1	50.8	-61.4	-24.3	-44.9	-14.0	67.6	6.5	−68.4%
2022	-4.6	11.9	0.0	-25.6	9.1	-13.7	0.0	37.2	-2.5	0.5	-5.1	13.0	+7.7%
2021	18.8	-5.6	11.9	-18.4	15.5	-2.9	-16.4	-11.1	6.4	-10.8	-26.8	-5.4	−43.9%
2020	27.7	-21.9	-7.6	40.1	-14.3	-41.0	4.2	-6.0	-3.4	-12.3	18.1	47.2	−6.0%
2019	10.0	7.6	-4.9	-8.9	-15.4	1.5	78.9	-71.0	-30.6	24.0	8.5	-20.0	−65.9%
2018	16.2	-18.3	-15.7	-25.5	3.6	-5.5	-2.9	-0.8	114.4	-10.6	-28.9	-33.3	−48.9%
2017	-26.9	-17.7	-30.8	-11.1	-12.5	88.6	-13.6	0.0	-17.5	-10.6	-20.6	-41.3	−81.9%
2016	0.0	0.0	12.5	-11.1	75.0	7.1	-6.7	0.0	-14.3	33.3	131.2	191.9	+1250.0%
2015	0.0	9.1	-16.7	0.0	10.0	-18.2	0.0	-11.1	0.0	0.0	-12.5	14.3	−27.3%
2014	12.5	11.1	-10.0	-11.1	37.5	0.0	0.0	27.3	-7.1	-15.4	-9.1	10.0	+37.5%
2013	16.7	28.6	0.0	11.1	-30.0	14.3	0.0	12.5	11.1	40.0	-21.4	-27.3	+33.3%
2012	42.9	-30.0	14.3	-12.5	0.0	0.0	28.6	-22.2	0.0	42.9	-20.0	-25.0	−14.3%
2011	60.0	-12.5	-14.3	0.0	16.7	14.3	50.0	-8.3	0.0	-9.1	-20.0	-12.5	+40.0%
2010	5.9	-1.1	-43.8	70.0	-11.8	-20.0	-16.7	-14.0	-7.0	-65.0	-42.9	-37.5	−94.1%
2009	-22.1	72.6	-23.1	-0.7	-32.2	23.8	-16.8	-23.1	20.0	0.0	-34.4	34.9	−41.4%
2008	-29.0	18.2	-13.5	-11.1	-17.5	-9.1	10.0	-6.1	9.7	-20.6	37.0	-21.6	−53.2%
2007	-14.3	50.0	-33.3	66.7	-10.0	11.1	0.0	-20.0	400.0	27.5	-19.6	-24.4	+342.9%

INSD

Insider Activity · BCDA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 28, 2026	Altman PeterChief Executive Officer	Purchase at price 1.03 per share.	1K	$1.03K
Sep 22, 2026	Altman PeterChief Executive Officer	Purchase at price 1.05 per share.	1.9K	$2.00K
Sep 2, 2026	Altman PeterChief Executive Officer	Purchase at price 1.09 per share.	800	$872
Aug 16, 2026	Altman PeterChief Executive Officer	Purchase at price 0.93 per share.	5.4K	$5.02K
Aug 12, 2026	Altman PeterChief Executive Officer	Purchase at price 0.92 per share.	1.9K	$1.75K
Jul 28, 2026	Altman PeterChief Executive Officer	Purchase at price 0.78 per share.	5K	$3.90K
Jul 16, 2026	Altman PeterChief Executive Officer	Purchase at price 0.83 per share.	500	$415
Jul 14, 2026	Altman PeterChief Executive Officer	Purchase at price 0.86 - 0.88 per share.	4.3K	$3.75K
Jul 9, 2026	Altman PeterChief Executive Officer	Purchase at price 0.90 - 0.97 per share.	7.5K	$7.17K
Jul 7, 2026	Altman PeterChief Executive Officer	Purchase at price 0.96 per share.	5.4K	$5.21K
Jun 28, 2026	Gillis Edward MOfficer	Stock Award(Grant) at price 1.20 per share.	39.5K	$47.42K
Jun 28, 2026	Mcclung DavidChief Financial Officer	Stock Award(Grant) at price 1.20 per share.	60.5K	$72.58K
Jun 28, 2026	Altman PeterChief Executive Officer	Stock Award(Grant) at price 1.20 per share.	110.6K	$132.75K
Jun 22, 2026	Stertzer Simon HDirector	Purchase at price 0.92 - 1.00 per share.	109.2K	$103.58K
Jun 17, 2026	Altman PeterChief Executive Officer	Purchase at price 0.85 - 0.96 per share.	2.3K	$2.04K
Jun 8, 2026	Altman PeterChief Executive Officer	Purchase at price 0.85 per share.	5K	$4.25K
May 19, 2026	Altman PeterChief Executive Officer	Purchase at price 0.92 - 0.95 per share.	1.7K	$1.57K
May 17, 2026	Altman PeterChief Executive Officer	Purchase at price 0.92 per share.	5.7K	$5.24K
May 14, 2026	Altman PeterChief Executive Officer	Purchase at price 1.02 per share.	5.1K	$5.20K
Apr 28, 2026	Altman PeterChief Executive Officer	Purchase at price 1.11 per share.	5K	$5.55K

BCDA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BCDA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BioCardia, Inc.

Seasonality · BCDA

Insider Activity · BCDA

Congress Trades · BCDA

Investors Holding BCDA

Investors Holding BCDA

Congress Trades · BCDA

Seasonality · BCDA

Insider Activity · BCDA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BioCardia, Inc.

Earnings & Dividends

News